Tilray (NASDAQ: TLRY)
|Date||Analyst Firm||Analyst Name||Action||Rating||Action Price||Prior Price||Target|
You can purchase shares of Tilray (NASDAQ: TLRY) through any online brokerage.
Other companies in Tilray’s space includes: CinCor Pharma (NASDAQ:CINC), Supernus Pharmaceuticals (NASDAQ:SUPN), Roivant Sciences (NASDAQ:ROIV), Axsome Therapeutics (NASDAQ:AXSM) and SIGA Technologies (NASDAQ:SIGA).
The latest price target for Tilray (NASDAQ: TLRY) was reported by Cantor Fitzgerald on Tuesday, August 2, 2022. The analyst firm set a price target for 4.15 expecting TLRY to rise to within 12 months (a possible 10.37% upside). 16 analyst firms have reported ratings in the last year.
The stock price for Tilray (NASDAQ: TLRY) is $3.76 last updated August 24, 2022, 8:00 PM UTC.
There are no upcoming dividends for Tilray.
Tilray’s Q1 earnings are confirmed for Thursday, October 6, 2022.
There is no upcoming split for Tilray.
Tilray is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.